Patents Examined by Marcia S. Noble
  • Patent number: 10228364
    Abstract: The present invention provides method for monitoring physiological status of an organ in a subject by monitoring morphological changes over time in transplanted tissue on an eye of the subject.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: March 12, 2019
    Assignee: BioCrine AB
    Inventor: Per-Olof Berggren
  • Patent number: 10226486
    Abstract: The present invention relates to a method for preparing induced dopaminergic neuronal progenitors (iDPs) comprising inducing an expression of Oct4, Sox2, Klf4, and c-Myc genes in adult cells and direct reprogramming of the adult cells to the iDPs by treating the cells with sonic hedgehog (SHH) and fibroblast growth factor 8 (FGF8); and a cell therapy product and a composition for treating or preventing Parkinson's Disease (PD) which comprises the iDPs as active ingredients. In addition to this, the present invention relates to a method for preparing midbrain dopaminergic neurons comprising isolating NSC-like colony by culturing the iDPs, dissociating the isolated NSC-like colony, and culturing the cells on the neural cell differentiation medium. Further, the present invention relates to a method for treating PD or a method for screening medicine for preventing or treating PD using the cells of the present invention.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: March 12, 2019
    Assignee: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Yee Sook Cho, Jang Hwan Kim, Han Seop Kim
  • Patent number: 10219883
    Abstract: The invention relates to methods of increasing genetic merit of swine by establishing a plurality of mating subtypes for a line of swine, and determining a percentage of progeny that are male for each of the mating subtypes, or a percentage of progeny that are female for each of the mating subtypes, that would result, relative to a control, in an increase in genetic merit in the line; the invention further relates to sorting a sperm cell sample from a male swine in one of the mating subtypes into one or more subpopulations of sperm cells, wherein a majority of sperm cells in a subpopulation of sperm cells bear X chromosomes or Y chromosomes, and inseminating one or more female swine in the one of the mating subtypes with the subpopulation of sperm cells to achieve the percentage of progeny that are male, or the percentage of progeny that are female, determined to increase genetic merit relative to the control.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: March 5, 2019
    Assignee: Inguran, LLC
    Inventors: Hein van der Steen, Gregg Bevier
  • Patent number: 10220056
    Abstract: The invention provides for methods and materials to decellularize a solid organ and to recellularize such a decellularized organ to thereby generate a solid organ.
    Type: Grant
    Filed: June 10, 2013
    Date of Patent: March 5, 2019
    Assignee: Miromatrix Medical, Inc.
    Inventors: Harald Ott, Doris Taylor
  • Patent number: 10214724
    Abstract: Methods for generating functional brain microvascular endothelial cells (BMECs) under chemically defined, serum-free conditions are provided. In particular, efficient and cost-effective methods for generating functional BMECs under chemically defined culture conditions are provided. BMECs obtained according to the methods provided herein are suitable for in vitro blood brain barrier (BBB) formation.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: February 26, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Tongcheng Qian, Eric V. Shusta, Sean P. Palecek
  • Patent number: 10196604
    Abstract: Disclosed are certain heterocyclic organic compounds that inhibit mitochondrial respiration and also lead to the maintenance of pluripotency of human embryonic stem cells in culture, even in the presence of oxygen. Exemplified are compounds, such as substituted 5-aminotetrazoles, which are reversible mitochondrial inhibitors. The pluripotency of the stem cells after culture is verified by the overexpression of pluripotent stem cell markers, exemplified by at least one of the genes NANOG, OCT4, and SURVIVIN after periods of culture in ambient oxygen.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: February 5, 2019
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Board of Regents of the University of Texas System
    Inventors: David Alvin Tyvoll, Christopher S. Navara, James P. Collman, Christopher Jeffrey Barile
  • Patent number: 10188082
    Abstract: The invention relates to methods of increasing the genetic progress of a line, breed or herd of swine through the use of sex-selected sperm cells in artificial insemination techniques. The invention also encompasses methods of artificially inseminating a swine via deep intrauterine catheter or via a laparoscopic procedure, which allow the use of reduced doses of sex-selected sperm cells.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: January 29, 2019
    Assignee: Inguran, LLC
    Inventors: Juan Moreno, Gregg Bevier, John Dobrinsky
  • Patent number: 10174341
    Abstract: The invention provides a herpes simplex virus (HSV) vector that does not express toxic HSV genes in non-complementing cells and which comprises a genome comprising one or more transgenes, wherein the vector is capable of expression of a transgene for at least 28 days in non-complementing cells. The disclosed vectors include vectors having deletions in the genes ICP0, ICP4, TCP22, TCP27 and TCP47, or alternative inactivating mutations, or vectors which express one or more of these genes with modified kinetics. The invention also relates to viral stocks of the inventive vectors, compositions thereof suitable for use therapeutically or for in vitro applications, and methods relating thereto. In another aspect, the invention provides a complementing cell, in particular a U20S cell, engineered to express ICP4 and ICP27 when the cell is infected with HSV for the production of the inventive vector. Said cells are disclosed as naturally complementing ICP0.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: January 8, 2019
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Joseph C. Glorioso, III, Justus Cohen, Yoshitaka Miyagawa, David Krisky, James Wechuck, Darren Wolfe
  • Patent number: 10172334
    Abstract: A transgenic animal is provided. In certain embodiments, the transgenic animal comprises a genome comprising: an immunoglobulin light chain locus comprising: a) a functional immunoglobulin light chain gene comprising a transcribed variable region encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of 2 to 5 different amino acids; and ii. a light chain framework; and, operably linked to the functional immunoglobulin light chain gene: b) a plurality of pseudogene light chain variable regions each encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of the same 2 to 5 different amino acids as the CDRs of the functional gene; and ii. a light chain framework that is identical in amino acid sequence to the light chain framework of the transcribed variable region.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: January 8, 2019
    Assignee: Crystal Bioscience Inc.
    Inventors: William Don Harriman, Robert Etches, Philip A. Leighton
  • Patent number: 10159754
    Abstract: In certain embodiments, the disclosure relates to compositions and methods relating to a translation-based gene regulation system that functions in mammalian cells. In certain specific embodiments, the disclosure relates to methods of regulating gene expression via modulating translation termination.
    Type: Grant
    Filed: January 8, 2013
    Date of Patent: December 25, 2018
    Assignee: The Children's Medical Center Corporation
    Inventors: Richard Mulligan, George J. Murphy
  • Patent number: 10159226
    Abstract: Systems for selecting, generating, and breeding hybrid dairy cattle are described, as are methods for maintaining herds of hybrid cattle.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: December 25, 2018
    Assignee: Genus PLC
    Inventors: Jon Lightner, Richard Williams
  • Patent number: 10155927
    Abstract: This application relates to a method for differentiating pluripotent stem cells (PSCs) into cardiomyocytes. Moreover this application relates to a method for differentiating human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) into defined cardiomyocytes based on linked steps of chemically defined medium inductions.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: December 18, 2018
    Assignee: HOFFMANN-LA-ROCHE INC.
    Inventors: Mark Burcin, Sonja Schlicht
  • Patent number: 10149914
    Abstract: Described are nucleic acid regulatory elements that are able to enhance liver-specific expression of genes, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. These are particularly useful for applications using gene therapy.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: December 11, 2018
    Assignees: VIB VZW, Life Sciences Research Partners VZW, Universiteit Gent
    Inventors: Marinee Chuah, Thierry Vandendriessche, Pieter De Bleser
  • Patent number: 10143187
    Abstract: In some aspects, the present invention provides chimeric transferrin receptor (TfR) polynucleotides and polypeptides. In other aspects, this invention provides chimeric TfR transgenic animal models and methods of using the animal models to identify therapeutics that can cross the blood-brain barrier.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: December 4, 2018
    Assignee: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Adam P. Silverman, Joy Yu Zuchero
  • Patent number: 10143708
    Abstract: The present invention is directed to methods of inhibiting cancer cell growth or proliferation by contacting the cancer cell with an extracellular matrix (ECM) composition. Also provided are methods of delivering a chemotherapeutic agent to a cancer cell by contacting a cancer cell with an extracellular matrix composition containing a chemotherapeutic agent. Also provided are compositions containing ECM and a chemotherapeutic agent.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: December 4, 2018
    Assignee: Histogen, Inc.
    Inventors: Gail K. Naughton, Emmett Pinney
  • Patent number: 10131882
    Abstract: The present invention relates in part to methods for producing tissue-specific cells from patient samples, and to tissue-specific cells produced using these methods. Methods for reprogramming cells using RNA are disclosed. Therapeutics comprising cells produced using these methods are also disclosed.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: November 20, 2018
    Assignee: FACTOR BIOSCIENCE INC.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 10131881
    Abstract: The present invention relates to a medium composition for the dedifferentiation of induced pluripotency stem cells, containing a phlorotannin fraction extracted and isolated from one type of brown algae selected from the group consisting of Ecklonia cava, Dictyopteris prolifera, Dictyota coriacea, Sargassum horneri, Ishige okamurai and the like. In addition, the present invention relates to a method for preparing induced pluripotency stem cells by using the medium composition. Induced pluripotency stem cells can be safely, easily and effectively prepared by using mesenchymal stem cells by using the medium composition of the present invention, and the prepared induced pluripotency stem cells can be differentiated into various cells, and thus can be useful as a cell therapeutic agent.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: November 20, 2018
    Assignee: BBHC
    Inventors: Sang Yeon Lee, Won Ju Jung, Ho Bin Kim, Min Sun Oh, Kye Ho Lee
  • Patent number: 10131879
    Abstract: An in vitro human neural multipotent, unipotent, or somatic cell possessing all of the following characteristics: is derived from the reprogramming of a somatic cell, a progenitor cell or a stem cell that exhibits at least a transient increase in intracellular levels of at least one reprogramming agent; is not differentiated from a pluripotent cell; expresses one or more markers of a multipotent, unipotent or somatic cell not characteristic of a neural stem cell, neural precursor cell, neural progenitor cell, neuroblast, or neuron; is not a cancerous cell; is stable and not artificially maintained by forced gene expression and may be maintained in standard neural stem cell media or neural media; and does not exhibit uncontrolled growth, teratoma formation, and tumor formation in vivo; wherein the cell comprises at least one polypeptide or an expression vector encoding at least one polypeptide selected from the group consisting of: Musashi1 (Msi1); Ngn2; Msi1 and Ngn2; Msi1 and methyl-CpG binding domain protei
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: November 20, 2018
    Assignee: GENESIS TECHNOLOGIES LIMITED
    Inventors: Jan-Eric Ahlfors, Rouwayda El-Ayoubi
  • Patent number: 10130080
    Abstract: The application provides, among others, methods for constructing animal obesity models, methods for screening microorganism or composition of microorganisms that may cause obesity, methods for screening therapeutic targets for treating metabolic disorders, and methods for screening or evaluating microorganisms, compounds, food, recipes, formulations, drugs, nutritional supplements, healthcare products, beverages and other items for preventing and treating metabolic diseases.
    Type: Grant
    Filed: August 1, 2013
    Date of Patent: November 20, 2018
    Assignees: SHANGHAI JIAO TONG UNIVERSITY, PERFECT (CHINA) CO., LTD.
    Inventors: Liping Zhao, Na Fei
  • Patent number: 10106771
    Abstract: Described herein are methods and related compositions for inducing differentiation of human pluripotent stem cells (hPSCs) into hemogenic endothelium with pan-myeloid potential or restricted potential, by forced expression in the hPSCs of a combination of transcription factors as described herein.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: October 23, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Igor Slukvin, Irina Elcheva